Using MRSA Screening Tests To Predict Methicillin Resistance in Staphylococcus aureus Bacteremia

Bloodstream infections withStaphylococcus aureus are clinically significant and are often treated with empirical methicillin resistance (MRSA, methicillin-resistantS. aureus ) coverage. However, vancomycin has associated harms. We hypothesized that MRSA screening correlated with resistance inS. aureus bacteremia and could help determine the requirement for empirical vancomycin therapy. We reviewed consecutiveS. aureus bacteremias over a 5-year period at two tertiary care hospitals. MRSA colonization was evaluated in three ways: as tested within 30 days of bacteremia (30-day criterion), as tested within 30 days but accounting for any prior positive results (ever-positive criterion), or as tested in known-positive patients, with patients with unknown MRSA status being labeled negative (known-positive criterion). There were 409S. aureus bacteremias: 302 (73.8%) methicillin-susceptibleS. aureus (MSSA) and 107 (26.2%) MRSA bacteremias. In the 167 patients with MSSA bacteremias, 7.2% had a positive MRSA test within 30 days. Of 107 patients with MRSA bacteremia, 68 were tested within 30 days (54 positive; 79.8%), and another 21 (19.6%) were previously positive. The 30-day criterion provided negative predictive values (NPV) exceeding 90% and 95% if the prevalence of MRSA inS. aureus bacteremia was less than 33.4% and 19.2%, respectively. The same NPVs were predicted at MRSA proportions below 39.7% and 23.8%, respectively, for the ever-positive criterion and 34.4% and 19.9%, respectively, for the known-positive criterion. In MRSA-colonized patients, positive predictive values exceeded 50% at low prevalence. MRSA screening could help avoid empirical vancomycin therapy and its complications in stable patients and settings with low-to-moderate proportions of MRSA bacteremia.